National Institutes of Health and Grantee Compliance With Federal Requirements To Ensure Proper Monitoring and Use of Grant Funds by Selected Grantees and Subgrantees
The National Institutes of Health (NIH) is the primary Federal agency that conducts and supports medical research. NIH funds grants, cooperative agreements, and contracts that support the advancement of fundamental knowledge about the nature and behavior of living systems. Approximately 80 percent of NIH funding goes to support research grants, including grants and subawards to support research conducted outside the United States. OIG has previously identified NIH's oversight of grants to foreign applicants as a potential risk to the Department meeting program goals and the appropriate use of Federal funds. NIH must manage and administer Federal awards to ensure that Federal funding is expended and associated programs are implemented in full accordance with statutory and public policy requirements. To do so, NIH must monitor grantee performance and grantee use of NIH funds. Grantees are responsible for complying with all requirements of the Federal award, including maintaining effective internal controls over the Federal award (45 CFR § 75.300 and § 75.305). Grantees that function as pass-through entities must monitor the activities of subrecipients, including foreign subrecipients, to ensure that subawards are used for authorized purposes in compliance with relevant laws and the terms and conditions of the subaward (45 CFR § 75.352). We will review NIH's monitoring of selected grants, and grantee use and management of NIH grant funds in accordance with Federal requirements.
Announced or Revised | Agency | Title | Component | Report Number(s) | Expected Issue Date (FY) |
---|---|---|---|---|---|
Completed | National Institutes of Health | National Institutes of Health and Grantee Compliance With Federal Requirements To Ensure Proper Monitoring and Use of Grant Funds by Selected Grantees and Subgrantees | Office of Audit Services | W-00-21-59461; A-05-21-00025 |
2023 |